Enzyme-Linked immunosorbent assay (ELISA) for IgA and IgG antibodies to epstein-barr-virus ribonucleotide reductase in patients with nasopharyngeal carcinoma
| Autor: | S. H. Chan, S. Y. Tsao, A. Fones-Tan, P. W. Khong, Y.Y. Gan, W. H. Tan, Ben Li, L. H. Gan |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Herpesvirus 4
Human Cancer Research Ribonucleotide Enzyme-Linked Immunosorbent Assay Reductase Antibodies Viral medicine.disease_cause Sensitivity and Specificity Virus law.invention law Ribonucleotide Reductases otorhinolaryngologic diseases medicine Humans biology Nasopharyngeal Neoplasms medicine.disease Epstein–Barr virus Virology Molecular biology Immunoglobulin A stomatognathic diseases Ribonucleotide reductase Oncology Nasopharyngeal carcinoma Immunoglobulin G Recombinant DNA biology.protein Antibody |
| Zdroj: | International Journal of Cancer. 59:739-742 |
| ISSN: | 1097-0215 0020-7136 |
| DOI: | 10.1002/ijc.2910590604 |
| Popis: | 661 bp coding for the carboxyl end of the large sub-unit of EBV ribonucleotide reductase was cloned into the pMal plasmid vector. Purified recombinant protein was tested in IgG and IgA ELISAs. For the IgG assay, 81 out of 100 NPC patients tested positive, whereas for the IgA assay, 60 tested positive. Among 100 normal individuals, I tested positive for the IgG assay and 9 tested positive for the IgA assay. The IgG assay picked up 6 out of 19 NPC sera which were IFA-VCA- and IFA-EA-negative for IgA antibodies. Hence the recombinant ribonucleotide reductase could have good potential as a diagnostic test for NPC or could serve as a complementary test to IFA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text